Cell and gene therapies are a promising frontier in biomedical innovation that have the potential to cure deadly and debilitating diseases. Over the past two years, several breakthrough therapies that treat cancers and genetic diseases have been approved by the FDA. Today there are more than 300 cell and gene therapies in development. While proliferation of these treatments may transform clinical outcomes, their high up-front costs and unique composition will likely challenge existing regulatory, financing, and delivery paradigms. During this briefing, panelists discussed factors policymakers must consider in order to support access to safe, effective, and affordable cell and gene therapies.
Rena Conti, Ph.D., Associate Research Director of Biopharma and Public Policy, Boston University Institute for Health System Innovation and Policy
John Glasspool, Senior Advisor, MIT Center for Biomedical Innovation: NEWDIGS, Financing and Reimbursement of Cures in the US (FoCUS) Project
Joanne Kurtzberg, M.D., Director of the Marcus Center for Cellular Cures (MC3), Duke University School of Medicine
Gillian Woollett, D.Phil., M.A., Vice President, Avalere Health
Sarah J. Dash, MPH, President and CEO, Alliance for Health Policy (moderator)